Raynovent and Qilu Pharmaceutical Reach Strategic Cooperation Agreement to Jointly Advance Commercialization of RAY1225 in China Region!
January 16, 2026, Guangzhou – Guangdong Raynovent Biotech Co., Ltd. ("Raynovent"), a majority-owned subsidiary of Guangdong Zhongsheng Pharmaceutical Co., Ltd., and Qilu Pharmaceutical Co., Ltd. ("Qilu Pharmaceutical") held a strategic cooperation signing ceremony, jointly announcing the execution of a licensing agreement for the innovative drug RAY1225 Injection, a GLP-1/GIP dual-target receptor ultra-long-acting agonist. Raynovent has granted Qilu Pharmaceutical the rights to manufacture and commercialize RAY1225 Injection within the China region (including Mainland China, Hong Kong, Macau, and Taiwan), while Raynovent retains all rights, title, and interests in the licensed intellectual property.
RAY1225 Injection is an innovative structured peptide drug developed by Raynovent with global independent intellectual property rights, possessing dual agonist activity for both GLP-1 and GIP receptors. Benefiting from excellent pharmacokinetic characteristics, it demonstrates ultra-long-acting drug potential with biweekly injection administration. Currently, the Phase III clinical trial (REBUILDING-2 study) evaluating the safety and efficacy of RAY1225 Injection for treating obese/overweight patients in China, the Phase III clinical trial (SHINING-3) comparing RAY1225 Injection in combination with oral hypoglycemic agents versus semaglutide injection for treating patients with type 2 diabetes, and the Phase III clinical trial (SHINING-2) evaluating RAY1225 Injection as monotherapy versus placebo for treating patients with type 2 diabetes have all successfully completed full participant enrollment. Raynovent will continue to uphold a rigorous attitude, advancing the Phase III clinical trials of RAY1225 Injection in a high-quality, efficient, and scientifically standardized manner.
Qilu Pharmaceutical possesses rich sales experience and outstanding commercialization capabilities. Leveraging Qilu Pharmaceutical's comprehensive market coverage across the entire pharmaceutical industry ecosystem and professional promotion capabilities, this establishes a solid foundation for building a strong, win-win strategic partnership between both parties. This collaboration will help leverage Raynovent's leading product advantages of RAY1225 Injection and Qilu Pharmaceutical's powerful commercialization strengths, further accelerating the future commercialization process of RAY1225 Injection in the China region and effectively meeting enormous domestic clinical needs.
Subject to the terms and conditions stipulated in the agreement, Raynovent will receive a total amount of RMB 1,000 million in upfront and milestone payments, including an upfront payment of RMB 200 million and development and sales milestones of up to RMB 800 million combined. Upon product launch, Raynovent will be entitled to receive double-digit sales royalties based on the net sales of the licensed product. Meanwhile, Raynovent will continue to be responsible for advancing clinical development and registration of relevant indications within the cooperation territory.
Dr. Xiaoxin Chen, Vice President of Zhongsheng Pharmaceutical and Chairman of Raynovent, stated:
"We are delighted to reach a commercialization cooperation agreement with Qilu Pharmaceutical for RAY1225 in the Greater China region. Among numerous interested cooperation partners, we ultimately selected Qilu Pharmaceutical as the commercialization partner for RAY1225 based on its leading position and outstanding commercialization capabilities in China's pharmaceutical industry. As a leading enterprise and pioneer in China's pharmaceutical sector, Qilu Pharmaceutical possesses a deeply penetrating sales network and excellent market access capabilities. We firmly believe that leveraging Qilu Pharmaceutical's powerful commercialization system, this cooperation will help us more efficiently deliver RAY1225, this innovative drug, to the vast population of obese/overweight and diabetic patients, providing them with safer and more effective treatment options."
About Raynovent
Guangdong Raynovent Biotech Co., Ltd. ("Raynovent") is a Sino-foreign joint venture enterprise dedicated to the research, development, and commercialization of innovative drugs for respiratory and metabolic diseases. Established in October 2018 with headquarters in Huangpu District, Guangzhou, China, Raynovent is a majority-owned subsidiary of the well-known A-share listed company "Guangdong Zhongsheng Pharmaceutical Co., Ltd."
Based on understanding and insights into the pathophysiology of respiratory and metabolic diseases, Raynovent focuses on developing novel therapies for major diseases and public health issues including influenza, COVID-19, avian influenza, idiopathic pulmonary fibrosis, non-alcoholic steatohepatitis (NASH), type 2 diabetes, and weight management.
Raynovent has established multiple global first-in-class or best-in-class drug pipelines at different development stages. Leritrevir tablets (Lerilin®), the world's first oral peptidomimetic monotherapy 3CL protease inhibitor for treating patients with mild to moderate COVID-19 infection, received drug registration certificates in 2023 and achieved industrialization. Compared to Pfizer's Paxlovid, leritrevir tablets can be used as monotherapy without co-administration with ritonavir, minimizing drug-drug interactions to the greatest extent and providing safer and more effective protection for high-risk COVID-19 populations, demonstrating significant clinical advantages. Onradivir tablets (Anruiwei®), the world's first influenza virus RNA polymerase PB2 inhibitor for treating adult simple influenza A, received marketing approval in May 2025, performing excellently across multiple key indicators and providing a new "Chinese solution" for global influenza prevention and control with characteristics of "rapid, potent, and low resistance." Onradivir for treating simple influenza in patients aged 2-17 has entered Phase III clinical trials. ZSP1601, China's first innovative drug approved for clinical trials for treating MASH, is currently in Phase IIb clinical trials. RAY1225 Injection, a long-acting GLP-1/GIP single-molecule dual agonist with global independent intellectual property rights for treating metabolic syndrome, has comprehensively launched Phase III clinical trials for treating obese/overweight patients and two Phase III clinical trials (SHINING-2 and SHINING-3) for treating patients with type 2 diabetes.
About Qilu Pharmaceutical
Qilu Pharmaceutical is a pharmaceutical industry group with patriotic sentiment, innovation genes, and international vision, operating 11 major production bases covering 9,160 mu of land with over 36,000 employees. Ranked third in the 2024 China Pharmaceutical Industry Top 100 list. The group consistently adheres to the core values of "Great Medicine with Sincerity, Serving the Nation and the World," closely aligning with the public's needs for healthy and beautiful lives, providing high-quality and trustworthy medicines to the world. With over 320 products launched cumulatively, including 79 domestically first-to-market/exclusive products. Products are exported to more than 100 countries and regions worldwide, benefiting approximately 1.5 billion patients annually. The group insists on "warm technological innovation," facing the world's technological frontiers, deploying six R&D platforms with China-US linkage, building a globally influential product pipeline, with nearly 300 branded generic drugs and over 20 biosimilars in development, and more than 80 innovative drugs at different clinical stages.